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In the current practice of anesthesia, each day, 
anesthesiologists deal with a great work: they use the 
cellular mechanisms of drug molecules to induce their 
desired effects for induction and maintenance of 
anesthesia for appropriate tolerance of surgery and its 
pain, modulation of the stress response, sedation 
needed for performing a variety of procedures, 
emergency anesthesia care, acute and chronic pain 
management or other everyday jobs of 
anesthesiologists in the perioperative period. 
Molecular anesthesia has been cited for more 
than 6 decades on a very limited scale. In 1956, the 
molecular mechanisms of morphine and pethidine are 
described (1). Pauling in 1961 published an article in 
Science describing a molecular theory for general 
anesthesia (2). 
In its report “the World in 2025”, Thomson 
Reuters has predicted clinical medicine would be the 
most active research front; while molecular biology 
has the 9th rank (3). But are we still practicing in the 
clinic the same as today? 
The future trend of anesthesia is highly 
dependent on finding the novel cellular and molecular 
mechanisms and the possible interactions of the 
newly discovered molecules and interaction 
mechanisms with organ systems. Today, we 
emphasize the role of pharmacologists, physiologists, 
immunologists, anatomists, embryologists, 
geneticists, cellular medicine specialists, physicists, 
and other basic science specialists; some very 
interesting examples are published in this volume of 
the Journal (4-7).  
However, changes that have been well started 
now would “revolutionize” our daily practice during 
the next decade in such a way that it will change the 
basis of medicine: presumably, we will have a new 
model of medicine known as “personalized medicine” 
or “precision medicine”. In this approach, the content 
of each patient’s genes accompanied with his/her 
cellular and molecular analysis is used as the basis for 
further diagnosis and treatment, tailoring the most 
appropriate treatment for each individual; some 
aspects of this novel approach like genetic makeup or 
genetic profile of an individual’s tumor is nowadays 
approved by FDA (8-10).  
In the approach of personalized medicine, not 
only clinical and psychological modalities are used 
for clinical management of patients, genetic, 
proteomic, and pharmacogenomic methods are used 
as well. Techniques are known as “bench techniques” 
are much more used in the clinic, at times even more 
than the conventional assessment tools and diagnostic 
methods (11, 12). Personalized medicine has started a 
few years ago and we will be incorporated in 
everyday practice; clinical anesthesia practice is not 
only excluded but seems to be among the front line 
fields due to the nature of anesthesia; especially when 
looking at the nearly 7 decades history of interactions 
between cellular and molecular medicine and 
anesthesia. 
Cellular and molecular anesthesia is going to 
pave its way from bench to bedside. Possibly, in the 
next years, the remnants of the arbitrary line between 
clinical and basic medicine are completely removed; 
this would not take too many years.  
The Thomson Reuters report “the World in 
2025” has very well quoted François Voltaire just the 
line after its title: “It is said that the present is 
pregnant with the future”. 
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